Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Disease and food allergy test kit supplier Omega Diagnostics said the Global Fund would include its HIV testing product in its global procurement list.
The inclusion meant that the Visitect CD4 advanced disease tests may be procured by organisations with access to the Global Fund or UNITAID funds.
The Global Fund requires the company to submit test for World Health Organisation prequalification review, in order to reach prequalification before the end of the ERPD authorised period which runs to 11 September 2020.
Omega said it had already submitted the product to the prequalification review process.
'I am delighted that we have received this response from ERPD that allows procurement access to our Visitect CD4 advanced disease test in certain circumstances and we look forward to providing a unique test to organisations which can help improve the health outcomes of many people living with HIV.'